


## Accepted Manuscript

Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience

R. Cravo, V. Rotman, P.M.N. Oliveira, H.G.T. Defendi, D.A. Conceição, J.R. Xavier, R. Chertkoff, T.G. Noronha, M.L.S. Maia



PII: S1079-9796(16)30260-1

DOI: doi: [10.1016/j.bcmed.2017.01.005](https://doi.org/10.1016/j.bcmed.2017.01.005)

Reference: YBCMD 2145

To appear in: *Blood Cells, Molecules and Diseases*

Received date: 1 November 2016

Revised date: 29 December 2016

Accepted date: 12 January 2017

Please cite this article as: R. Cravo, V. Rotman, P.M.N. Oliveira, H.G.T. Defendi, D.A. Conceição, J.R. Xavier, R. Chertkoff, T.G. Noronha, M.L.S. Maia , Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ybcmd(2017), doi: [10.1016/j.bcmed.2017.01.005](https://doi.org/10.1016/j.bcmed.2017.01.005)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## TALIGLUCERASE ALFA IN GAUCHER DISEASE: DESCRIPTION OF A BRAZILIAN EXPERIENCE

Cravo R<sup>1</sup>, Rotman V<sup>2</sup>, Oliveira PMN<sup>2</sup>, Defendi HGT<sup>2</sup>, Conceição DA<sup>2</sup>, Xavier JR<sup>2</sup>, Chertkoff R<sup>3</sup>, Noronha TG<sup>2</sup>, Maia MLS<sup>2</sup>

1. Hemorio Hospital, Rio de Janeiro, Brazil; 2. BIO-Manguinhos / Oswaldo Cruz Institute, Rio de Janeiro, Brazil; 3. Protalix Biotherapeutics, Carmiel, Israel

Corresponding Author: Vivian Rotman, MD, PhD. Email: [vrotman@gmail.com](mailto:vrotman@gmail.com) or [vivian.rotman@bio.fiocruz.br](mailto:vivian.rotman@bio.fiocruz.br). Rua Reseda, 23/401. Rio de Janeiro. Brazil.

Zip code: 22471-230. Telephone Number: +55 21 8822-4889

Email addresses: [renata.cravo@hemorio.rj.gov.br](mailto:renata.cravo@hemorio.rj.gov.br); [vivian.rotman@bio.fiocruz.br](mailto:vivian.rotman@bio.fiocruz.br); [Patricia.mouta@bio.fiocruz.br](mailto:Patricia.mouta@bio.fiocruz.br); [Hugo.defendi@bio.fiocruz.br](mailto:Hugo.defendi@bio.fiocruz.br); [Daraujo@bio.fiocruz.br](mailto:Daraujo@bio.fiocruz.br); [janaina.xavier@bio.fiocruz.br](mailto:janaina.xavier@bio.fiocruz.br); [raul@protalix.com](mailto:raul@protalix.com); [Tnoronha@bio.fiocruz.br](mailto:Tnoronha@bio.fiocruz.br); [lourdes.maia@bio.fiocruz.br](mailto:lourdes.maia@bio.fiocruz.br)

### **Abstract:**

We evaluated retrospectively, efficacy and safety of taliglucerase alfa for Gaucher Disease in a Brazilian population. Thirteen patients were included for efficacy analysis only one of them naïve to enzyme replacement therapy. All the parameters evaluated remained stable throughout treatment (mean duration 3,5 years). Only three patients (out of 35) had to discontinue treatment due to a serious adverse event. In conclusion, treatment with taliglucerase alfa was found to be safe and efficient.

**Keywords:** Gaucher disease; lysosomal storage diseases; enzyme replacement therapy; taliglucerase alfa; imiglucerase; velaglucerase

**Abbreviations:** GD, Gaucher disease; ERT, enzyme replacement therapy; FDA, Food and Drug Administration, AST, aspartate aminotransferase; ALT, alanine aminotransferase; SOC, System Organ Classification;

Download English Version:

<https://daneshyari.com/en/article/8648104>

Download Persian Version:

<https://daneshyari.com/article/8648104>

[Daneshyari.com](https://daneshyari.com)